Insider filing · NBIX
Matt Abernethy
Chief Financial Officer
profile →
Neurocrine Biosciences, Inc.
NBIX · Healthcare · 59 filings in 24 months
ticker →
Matt Abernethy sold $363K of Neurocrine Biosciences (NBIX)
Executed Sep 14, disclosed Sep 15, 1 day later.
Value, as filed
$363K
2,311 sh × $157.20
Executed
Sep 14
the trade date, as filed
Disclosed
Sep 15
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MAMatt Abernethy (Chief Financial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $363K of NBIX (2,311 sh × $157.20, as filed), executed Sep 14.
The name
NBIXHealthcare · Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunolog…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Matt Abernethy in NBIX
NBIXSALE
Neurocrine Biosciences, Inc.
$299K2,558 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $116K
980 sh × $118.27
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $196K
1,283 sh × $152.87
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET